National Center for Natural Products Research, School of Pharmacy, University of Mississippi, MS 38677, USA.
Bioorg Med Chem Lett. 2012 Feb 15;22(4):1701-4. doi: 10.1016/j.bmcl.2011.12.108. Epub 2012 Jan 3.
8-Aminoquinolines (8-AQs) are important class of anti-infective therapeutics. 5-Phenoxy 8-aminoquinoline analogs have shown improved metabolic stability compared to primaquine. In view or predictive role of monoamine oxidases (MAO) in metabolism of 8-aminoquinolines the 5-phenoxy analogs were evaluated in vitro for the inhibition of recombinant human MAO-A and MAO-B. The analogs were several folds more potent inhibitors of MAO-A and MAO-B compared to primaquine, the parent drug, with selectivity for MAO-B. 5-(4-Trifluoromethylphenoxy)-4-methylprimaquine (6) Inhibited MAO-B with IC(50) value of 150 nM (626-fold more potent than primaquine). These results will have important implications in optimizing metabolic stability of 8-AQs to improve therapeutic value and also indicate scope for development of 8-AQs as selective MAO inhibitors.
8-氨基喹啉(8-AQs)是一类重要的抗感染治疗药物。5-苯氧基 8-氨基喹啉类似物与伯氨喹相比显示出改善的代谢稳定性。鉴于单胺氧化酶(MAO)在 8-氨基喹啉代谢中的预测作用,对 5-苯氧基类似物进行了体外评估,以抑制重组人 MAO-A 和 MAO-B。与母体药物伯氨喹相比,类似物对 MAO-A 和 MAO-B 的抑制作用要强几个数量级,对 MAO-B 具有选择性。5-(4-三氟甲氧基苯氧基)-4-甲基伯氨喹(6)对 MAO-B 的抑制作用的 IC50 值为 150 nM(比伯氨喹强 626 倍)。这些结果对于优化 8-AQs 的代谢稳定性以提高治疗价值具有重要意义,并且表明可以将 8-AQs 开发为选择性 MAO 抑制剂。